Reviews Idarubicin


No reviews yet.

Idamycin Drug Description
Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly
into a freely flowing intravenous infusion. It must never be given
intramuscularly or subcutaneously. Severe local tissue necrosis can occur
if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN can cause myocardial
toxicity leading to congestive heart failure. Cardiac toxicity is more common
in patients who have received prior anthracyclines or who have preexisting
cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when
IDAMYCIN is used at effective therapeutic doses.
It is recommended that IDAMYCIN be administered only under the supervision
of a physician who is experienced in leukemia chemotherapy and in facilities
with laboratory and supportive resources adequate to monitor drug tolerance
and protect and maintain a patient compromised by drug toxicity. The physician
and institution must be capable of responding rapidly and completely to severe
hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function.
(See DOSAGE AND ADMINISTRATION.)


DRUG DESCRIPTION
IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic
antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride
is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride,
(7S-cis). The structural formula is as follows:







C26H27NO9•Hcl          
M.W 533.96
IDAMYCIN, a sterile lyophilized powder for reconstitution and intravenous administration,
is available in a 20 mg single use only vial.
Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of
Lactose NF (hydrous) as an orange-red, lyophilized powder.Last reviewed on RxList: 10/9/2008




Idamycin Drug Description
Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly
into a freely flowing intravenous infusion. It must never be given
intramuscularly or subcutaneously. Severe local tissue necrosis can occur
if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN can cause myocardial
toxicity leading to congestive heart failure. Cardiac toxicity is more common
in patients who have received prior anthracyclines or who have preexisting
cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when
IDAMYCIN is used at effective therapeutic doses.
It is recommended that IDAMYCIN be administered only under the supervision
of a physician who is experienced in leukemia chemotherapy and in facilities
with laboratory and supportive resources adequate to monitor drug tolerance
and protect and maintain a patient compromised by drug toxicity. The physician
and institution must be capable of responding rapidly and completely to severe
hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function.
(See DOSAGE AND ADMINISTRATION.)


DRUG DESCRIPTION
IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic
antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride
is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride,
(7S-cis). The structural formula is as follows:







C26H27NO9•Hcl          
M.W 533.96
IDAMYCIN, a sterile lyophilized powder for reconstitution and intravenous administration,
is available in a 20 mg single use only vial.
Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of
Lactose NF (hydrous) as an orange-red, lyophilized powder.Last reviewed on RxList: 10/9/2008




Idamycin Drug Description
Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly
into a freely flowing intravenous infusion. It must never be given
intramuscularly or subcutaneously. Severe local tissue necrosis can occur
if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN can cause myocardial
toxicity leading to congestive heart failure. Cardiac toxicity is more common
in patients who have received prior anthracyclines or who have preexisting
cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when
IDAMYCIN is used at effective therapeutic doses.
It is recommended that IDAMYCIN be administered only under the supervision
of a physician who is experienced in leukemia chemotherapy and in facilities
with laboratory and supportive resources adequate to monitor drug tolerance
and protect and maintain a patient compromised by drug toxicity. The physician
and institution must be capable of responding rapidly and completely to severe
hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function.
(See DOSAGE AND ADMINISTRATION.)


DRUG DESCRIPTION
IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic
antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride
is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride,
(7S-cis). The structural formula is as follows:







C26H27NO9•Hcl          
M.W 533.96
IDAMYCIN, a sterile lyophilized powder for reconstitution and intravenous administration,
is available in a 20 mg single use only vial.
Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of
Lactose NF (hydrous) as an orange-red, lyophilized powder.Last reviewed on RxList: 10/9/2008




Idamycin Drug Description
Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly
into a freely flowing intravenous infusion. It must never be given
intramuscularly or subcutaneously. Severe local tissue necrosis can occur
if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN can cause myocardial
toxicity leading to congestive heart failure. Cardiac toxicity is more common
in patients who have received prior anthracyclines or who have preexisting
cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when
IDAMYCIN is used at effective therapeutic doses.
It is recommended that IDAMYCIN be administered only under the supervision
of a physician who is experienced in leukemia chemotherapy and in facilities
with laboratory and supportive resources adequate to monitor drug tolerance
and protect and maintain a patient compromised by drug toxicity. The physician
and institution must be capable of responding rapidly and completely to severe
hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function.
(See DOSAGE AND ADMINISTRATION.)


DRUG DESCRIPTION
IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic
antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride
is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride,
(7S-cis). The structural formula is as follows:







C26H27NO9•Hcl          
M.W 533.96
IDAMYCIN, a sterile lyophilized powder for reconstitution and intravenous administration,
is available in a 20 mg single use only vial.
Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of
Lactose NF (hydrous) as an orange-red, lyophilized powder.Last reviewed on RxList: 10/9/2008




Idamycin Drug Description
Idamycin®
(idarubicin hydrochloride) for Injection, USP

WARNINGS

IDAMYCIN (idarubicin hydrochloride for injection, USP) should be given slowly
into a freely flowing intravenous infusion. It must never be given
intramuscularly or subcutaneously. Severe local tissue necrosis can occur
if there is extravasation during administration.
As is the case with other anthracyclines the use of IDAMYCIN can cause myocardial
toxicity leading to congestive heart failure. Cardiac toxicity is more common
in patients who have received prior anthracyclines or who have preexisting
cardiac disease.
As is usual with antileukemic agents, severe myelosuppression occurs when
IDAMYCIN is used at effective therapeutic doses.
It is recommended that IDAMYCIN be administered only under the supervision
of a physician who is experienced in leukemia chemotherapy and in facilities
with laboratory and supportive resources adequate to monitor drug tolerance
and protect and maintain a patient compromised by drug toxicity. The physician
and institution must be capable of responding rapidly and completely to severe
hemorrhagic conditions and/or overwhelming infection.
Dosage should be reduced in patients with impaired hepatic or renal function.
(See DOSAGE AND ADMINISTRATION.)


DRUG DESCRIPTION
IDAMYCIN® (idarubicin hydrochloride for injection, USP) is a sterile, semi-synthetic
antineoplastic anthracycline for intravenous use. Chemically, idarubicin hydrochloride
is 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride,
(7S-cis). The structural formula is as follows:







C26H27NO9•Hcl          
M.W 533.96
IDAMYCIN, a sterile lyophilized powder for reconstitution and intravenous administration,
is available in a 20 mg single use only vial.
Each 20 mg vial contains 20 mg Idarubicin Hydrochloride, USP and 200 mg of
Lactose NF (hydrous) as an orange-red, lyophilized powder.Last reviewed on RxList: 10/9/2008





Other reviews about Idarubicin on wordpress

Puzzled
  by jesswedehart
My mom was given Cytarabine and Idarubicin, as chemotherapy treatment for acute myeloid leukemia. It killed all of her cancer cells for the time being. Her body is […]


Day 4 - early evening
  by Seth
So during the day, I spoke with my oncologist. I have Acute Myelogenous Leukemia. I can't explain how this is different from the other type. We also discussed […]


So long, free and single life...
  by kballantine
I've entered into a long term commitment. With an IV stand on wheels. My days of freedom, wandering, and independence are over.   I have been inextricably linked to […]


The 'hand-foot syndrome': cancer drugs may cause the vanishing of fingerprints!
  by handfacts
The 'hand-foot syndrome' can be understood as a side effect of a chemotherapy - especially the cancer drug Capecitabine (Xeloda) is notorious for the side-effects related to the […]


Woman killed by cancer drug overdose
  by percyweller
A jury has ruled that the death of a woman from a lethal overdose of a cancer drug was manslaughter by gross neglect. Anna McKenna died when she was […]


The Clinic
  by cataldo11
Sitting at the clinic now.  What is the clinic?  It is the "state of the art" out-patient clinic for the Blood and Marrow Group of GA, Patrick's oncologist.  […]


Global Non Small Cell Lung Cancer/Oncology Drugs Market
  by marketsandmarkets
Original Source: Lung Cancer Drugs Market Buy Now: Lung Oncology Drugs Market INTRODUCTION To define and intensively analyze the Global Non Small Cell Lung Cancer/Oncology […]


Doctor's Appointment... Check
  by tokenhippygirl
Met with Dr. Bigler today. All went well and we are a go for the next round. We go into the hospital tomorrow at 8:00 and […]


Back Home With a New Bed
  by tokenhippygirl
Yep folks...  came home yesterday, for those who didn't already see it on Facebook.  Sorry I didn't blog, but it was sort of a long day and I […]



Other reviews about Idarubicin on web:

Idarubicin (pronounced /ˌaɪdəˈruːbɨsɪn/) or 4-demethoxydaunorubicin is an anthracycline antileukemic drug that is currently combined with cytosine arabinoside as a first line ... Idarubicin - Wikipedia, the free encyclopedia


Accurate, FDA approved Idarubicin information for healthcare professionals and patients - brought to you by Drugs.com. Idarubicin Official FDA information, side effects and uses.


Idarubicin Key Terms: Bilirubin , Blasts , Complete remission . Definition Idarubicin is a medication that kills cancer cells Idarubicin: Definition from Answers.com


Idarubicin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an anthracyline antitumor antibiotic. Idamycin, Idamycin PFS Idarubicin, Idamycin - Chemotherapy Drugs, Chemo Drug Side Effects


All about Idarubicin. View complete and up to date Idarubicin information - part of the Drugs.com trusted medication database. Idarubicin Facts and Comparisons at Drugs.com


Learn about the prescription medication Idamycin (Idarubicin), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Idamycin (Idarubicin) Drug Information: Uses, Side Effects, Drug ...


Learn more about Idarubicin. Find the Web's best health guides, medical reports, news, videos and tools for Idarubicin. Share Idarubicin experiences and get advice from experts. Idarubicin Overview - References, Advice, News, Videos, Coping ...


Drug details for Idarubicin. ... Idarubicin is given intravenously. How It Works. Idarubicin kills cancer cells by stopping their growth. Idarubicin


Idarubicin is used to treat certain kinds of leukemia (AML and other non-lymphocytic types) along with other drugs. Idarubicin


Consumer information about the medication IDARUBICIN - INJECTION (Idamycin), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... IDARUBICIN - INJECTION (Idamycin) side effects, medical uses, and ...





Featured Reviews

Reviews Nuromax

Nuromax Drug Description NUROMAX (doxacurium chloride) Injection This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. DRUG DESCRIPTION NUROMAX (doxacurium...
Read More  |  Review This
Reviews Interferon Gamma 1 b

Actimmune Drug Description ACTIMMUNE® (interferon gamma-1 b) DRUG DESCRIPTION What are the possible side effects of interferon gamma-1b (Actimmune)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Loracarbef

Lorabid Drug Description DRUG DESCRIPTION What are the possible side effects of loracarbef (Lorabid, Lorabid Pulvules)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing;...
Read More  |  Review This
Reviews Carnitor Injection

Carnitor Injection Drug Description CARNITOR® (levocarnitine) Injection 1 g per 5 mL vial FOR INTRAVENOUS USE ONLY. DRUG DESCRIPTION CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids...
Read More  |  Review This
Reviews Regranex

Regranex Drug Description Regranex® Gel 0.01% (becaplermin) WARNING An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of REGRANEX Gel in a post-marketing retrospective...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....